Kevin D. Freeman‐Cook
Plex Pharmaceuticals (United States)(US)IMGENEX India (India)(IN)
Publications by Year
Research Areas
Peptidase Inhibition and Analysis, Advanced Breast Cancer Therapies, Computational Drug Discovery Methods, Chromatin Remodeling and Cancer, Plant biochemistry and biosynthesis
Most-Cited Works
- → Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor(2021)172 cited
- → Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A(2017)131 cited
- → Lipophilic Efficiency: The Most Important Efficiency Metric in Medicinal Chemistry(2013)126 cited
- → Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer(2021)112 cited
- → Design of Selective, ATP-Competitive Inhibitors of Akt(2010)75 cited
- → Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus(2011)68 cited